



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/664,444	09/18/2000	John C Bell	2370-63	4773
75	90 03/20/2002			
Lewis J Kreisl	er		EXAMI	NER
Legal Departme 930 Clopper roa	d		ZEMAN, ROBERT	
Gaithersburg, M	ID 20878		ART UNIT	PAPER NUMBER
			1645	iU
			DATE MAILED: 03/20/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)						
•	09/664,444	BELL ET AL.						
Office Action Summary	Examiner	Art Unit						
	Robert A Zeman	1645						
The MAILING DATE of this communication								
Period for Reply		·						
A SHORTENED STATUTORY PERIOD FOR RE THE MAILING DATE OF THIS COMMUNICATIO  - Extensions of time may be available under the provisions of 37 CFF after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a  - If NO period for reply is specified above, the maximum statutory per Failure to reply within the set or extended period for reply will, by st  - Any reply received by the Office later than three months after the m earned patent term adjustment. See 37 CFR 1.704(b).  Status	N. R 1.136(a). In no event, however, may reply within the statutory minimum of the riod will apply and will expire SIX (6) More atute, cause the application to become	a reply be timely filed  nirty (30) days will be considered timely.  DNTHS from the mailing date of this communication.  ABANDONED (35 U.S.C. § 133).						
1) Responsive to communication(s) filed on	18 September 2000 .							
2a) ☐ This action is <b>FINAL</b> . 2b) ☑	This action is non-final.							
Since this application is in condition for all closed in accordance with the practice uno Disposition of Claims	owance except for formal m der <i>Ex parte Quayle</i> , 1935 (	atters, prosecution as to the merits is C.D. 11, 453 O.G. 213.						
4)⊠ Claim(s) <u>1-63</u> is/are pending in the applica	ition.							
4a) Of the above claim(s) is/are with	drawn from consideration.							
5) Claim(s) is/are allowed.								
6) Claim(s) is/are rejected.	6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.	7) Claim(s) is/are objected to.							
8) Claim(s) <u>1-63</u> are subject to restriction and	or election requirement.							
Application Papers								
9) The specification is objected to by the Exam		w =						
10) The drawing(s) filed on is/are: a) a								
Applicant may not request that any objection t								
11) The proposed drawing correction filed on		disapproved by the Examiner.						
If approved, corrected drawings are required in 12) The oath or declaration is objected to by the								
,	, Examinor.							
Priority under 35 U.S.C. §§ 119 and 120  13) Acknowledgment is made of a claim for for	oian priority under 35 H S C	: 8 119(a)-(d) or (f)						
a) All b) Some * c) None of:	eigh phonty under 50 0.0.c	. 3 1 10(a) (a) c. (i).						
/ <del></del> /	ants have been received							
<ul> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> </ul>								
<ul> <li>3.</li></ul>	l Bureau (PCT Rule 17.2(a)	).						
14) Acknowledgment is made of a claim for dom	nestic priority under 35 U.S.	C. § 119(e) (to a provisional application	n).					
<ul> <li>a)    The translation of the foreign language</li> <li>15)    Acknowledgment is made of a claim for dom</li> </ul>								
Attachment(s)								
Notice of References Cited (PTO-892)     Notice of Draftsperson's Patent Drawing Review (PTO-948 )    Information Disclosure Statement(s) (PTO-1449) Paper No	5) Notice	w Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO-152)						

Application/Control Number: 09/664,444

Art Unit: 1645

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-4, 18-22 and 24-37, drawn to a method of reducing the viability of carcinoma cells by administering a virus, classified in class 424, subclass 93.1.
- II. Claims 1, 5-13, 18-37, drawn to a method of reducing the viability of hematopoietic tumor cells by administering a virus, classified in class 424, subclass 93.1.
- III. Claims 1, 18-22 and 24-37, drawn to a method of reducing the viability of glioblastoma cells by administering a virus, classified in class 424, subclass 93.1.
- IV. Claims 1, 18-22 and 24-37, drawn to a method of reducing the viability of melanoma cells by administering a virus, classified in class 424, subclass 93.1.
- V. Claims1, 14-16, 18-22 and 24-37, drawn to a method of reducing the viability of sarcoma cells by administering a virus, classified in class 424, subclass 93.1.
- VI. Claims 1, 17-22 and 24-37, drawn to a method of reducing the viability of neuroendocrine tumor cells by administering a virus, classified in class 424, subclass 93.1.
- VII. Claims 38-51, drawn to a method of identifying a tumor susceptible to treatment with a virus, classified in class 424, subclass 9.2.
- VIII. Claims 52-55, drawn to methods of purifying virus, classified in class 435, subclass 248.

Application/Control Number: 09/664,444

Art Unit: 1645

- IX. Claims 56-58, drawn to modified viruses, classified in class 435, subclass 235.1.
- X. Claim 59, drawn to a nucleic acid encoding VSV protein N, classified in class 536, subclass 23.1.
- XI. Claim 60, drawn to a nucleic acid encoding VSV protein P, classified in class 536, subclass 23.1.
- XII. Claim 61, drawn to a nucleic acid encoding VSV protein M, classified in class 536, subclass 23.1.
- XIII. Claim 62, drawn to a nucleic acid encoding VSV protein G, classified in class 536, subclass 23.1.
- XIV. Claim 63, drawn to a nucleic acid encoding VSV protein L, classified in class 536, subclass 23.1.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-VIII are separate and distinct from each other as they are drawn to differing methods having different steps and leading to differing results.

Inventions IX-XIV are separate and distinct from each other as they comprise differing biochemical and physical entities having differing properties and uses. Invention IX is drawn to modified viruses, whereas Inventions X-XIII are drawn to nucleic acids

Inventions X-XIV are separate and distinct from Inventions I-VI as the substances of Inventions X-XIV cannot be used in the methods of Inventions I-VI.

Invention IX and Inventions I-VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the Application/Control Number: 09/664,444

Art Unit: 1645

process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the viruses of Invention IX can be used in other methods such as antibody production.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A Zeman whose telephone number is (703) 308-7991. The examiner can normally be reached on M-Th 7:30 am - 5:00 pm and Alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Donna Wortman can be reached on (703) 308-1032. The fax phone numbers for the Application/Control Number: 09/664,444 Page 5

Art Unit: 1645

organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Robert A. Zeman March 11, 2002